Safety and Feasibility of Repeated Intrathecal Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells in Patients with Neurological Diseases

Table 6

Clinical studies of intrathecal allogeneic MSCs described in the literature.

Authors/country	Diagnosis	No. of treated patients	Stem cell type	Transplant type	Dose per injection	Injection frequency	Follow-up	Adverse event (person-time)
Jin et al. [36]/China	SCA	16	UCMSCs	IT+IV		3, weekly	12 months	Fever (1); dizziness (2); headache (2)
Lv et al. [38]/China	Autism	9	UCMSCs	IT+IV		2, at 5–7-day intervals	6 months	Fever (2)
Wang et al. [39]/China	TBI	20	UCMSCs	IT		4, at 5–7 day intervals	6 months	Dizziness (4); headache (4)
Liu et al. [37]/China	SCI	22	UCMSCs	IT		4–12, weekly	3–36 months	Lumbago (1); headache (1)

Abbreviations: SCA, hereditary spinocerebellar ataxia; SCI, spinal cord injury; TBI, traumatic brain injury; UCMSCs, umbilical cord mesenchymal stem cells; IT, intrathecal; IV, intravenous.